Does dehydroepiandrosterone (DHEA) improve IVF outcomes in poor responders?

Not Applicable

Completed

• Conditions: Infertility; Pregnancy and Childbirth

• Registration Number: ISRCTN78447218
• Lead Sponsor: Homerton University Hospital NHS Foundation Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-10-29
• Study Completion: 2020-12-31
• Last Update Posted: 21 February 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 400

Inclusion Criteria

Current inclusion criteria as of 24/10/2017:
Inclusion criteria are based on the ESHRE definition of poor responders and would include any patient with any two of the following:
1. Age = 40 years
2. Markers for poor ovarian reserve (AMH <7 pmol/L(<1.1 ng/ml) and/or AFC< 7)
3. Previous poor response to ovarian stimulation ( =3 oocytes with a conventional stimulation protocol)

Previous inclusion criteria:
European Society of Human Reproduction and Embryology (ESHRE) criteria for poor responders:
1. Age > 40 years
2. Markers for poor ovarian reserve [Anti-Mullerian Hormone (AMH) < 0.5 ng/ml (5 pmol/L), Follicle-Stimulating Hormone (FSH) > 15 IU, Antral Follicle Counts (AFC) < 6]
3. Previous poor response to ovarian stimulation (less than three mature follicles on day of hCG trigger/cycle cancellation due to poor response/less than three oocytes retrieved)

Exclusion Criteria

Current exclusion criteria as of 24/10/2017:
1. Women ?42 years
2. Women with premature ovarian failure/premature menopause (FSH>40 U/L)
3. Women already taking DHEA.
4. Patients with a known allergy to the trial drug or any of the active ingredients in the placebo

Previous exclusion criteria:
1. Women > 42 years
2. Women with premature ovarian failure/premature menopause (FSH > 40 U/L)

Study & Design

• Study Type: Interventional
• Study Design: Not specified